<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>
SALT LAKE CITY, Nov. 29, 2021 /PRNewswire/ — Co-Diagnostics, Inc. (Nasdaq: CODX) (the “Company”), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, reported today that none of the mutations in the heavily mutated SARS-CoV-2 variant recently discovered in Africa are predicted to interfere with any of the Company’s suite of COVID-19 PCR diagnostic assays. None of the mutations in the Omicron variant interfere with any of the Company’s COVID-19 PCR diagnostic assays The new coronavirus strain includes more than 50 mutations, over 30 of which are found on the virus’s spike protein, the main target of the body’s immune responses, and is currently being studied to determine whether the mutations lead to increased transmissibility or ability to evade the body’s immune response.
...read full article on PRNewsWire
